|
Company:
|
ONCORUS, INC. (ONCR)
|
|
Form Type:
|
8-K
|
|
Filing Date:
|
6/23/2022
|
|
CIK:
|
0001671818
|
|
Address:
|
4 CORPORATE DRIVE
|
|
City, State, Zip:
|
ANDOVER, Massachusetts 01810
|
|
Telephone:
|
857-320-6400
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$0.11
|
Change:
0.004 (4.02%)
|
Trade Time:
Jun 07
|
Market Cap:
$2.77M
|
|
|
|
|
|
|
Description of Business
|
|
We are a preclinical-stage biopharmaceutical company focused on the intravenous
administration of self-amplifying RNA to transform outcomes for cancer patients.
We believe that our product candidates have the potential to bring significant
benefit to patients who are currently underserved by approved immuno-oncology
therapies, including other viral immunotherapies and immune checkpoint
inhibitors.
Our self-amplifying RNA immunotherapy platform improves upon key characteristics
of this therapeutic class to enhance systemic activity. Our approach involves
encapsulating genomes of RNA viruses known to kill cancer cells within a lipid
nanoparticle, or LNP, creating a selectively self-amplifying vRNA immunotherapy
to be administered intravenously, or IV.
|
|
|
|